XencorNASDAQ: XNCR

Xencor (XNCR) has the optimal mix of factors for a potential earnings surpass in its upcoming report. Make sure you are ready with the essential expectations.

Xencor (XNCR) experienced a surge in stock price during the previous session with higher-than-average trading volume. However, recent changes in earnings estimates for the stock do not indicate continued strength in the future.

Xencor (XNCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.36. This compares to loss of $0.20 per share a year ago.

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results, provide a.

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate shareholder value. The global metastatic castration-resistant prostate cancer treatment market is expected to reach $17.71 billion by 2029. Xencor is also planning to evaluate vudalimab in combination with chemotherapy for the treatment of patients with non-small cell lung cancer; the Study is expected to start before the end of 2023.

Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and licensing agreements for approved molecules in hematologic cancers and blood disorders. Xencor's pipeline includes promising drugs like vudalimab, a bispecific antibody, but timing and toxicity concerns may impact their valuation.